{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:06:45Z","timestamp":1759334805679,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jaad.2014.01.875","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T04:58:43Z","timestamp":1402981123000},"page":"1.e1-1.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor\u2013alfa antagonists"],"prefix":"10.1016","volume":"71","author":[{"given":"Lisa M.","family":"Chirch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip R.","family":"Cataline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin D.","family":"Dieckhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2014.01.875_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol"},{"volume":"Vol 1","year":"2010","key":"10.1016\/j.jaad.2014.01.875_bib2"},{"key":"10.1016\/j.jaad.2014.01.875_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","article-title":"Infections associated with tumor necrosis factor-alpha antagonists","volume":"84","author":"Crum","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2014.01.875_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/pmj.78.915.47","article-title":"Necrotizing fasciitis in a patient receiving infliximab for rheumatoid arthritis","volume":"78","author":"Chan","year":"2002","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jaad.2014.01.875_bib5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4065\/83.3.343","article-title":"Coccidioidomycosis","volume":"83","author":"Parish","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaad.2014.01.875_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/CMR.00027-06","article-title":"Histoplasmosis: a clinical and laboratory update","volume":"20","author":"Kauffman","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2014.01.875_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0891-5520(02)00039-9","article-title":"Histoplasmosis","volume":"17","author":"Wheat","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jaad.2014.01.875_bib8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2165\/00003495-200969110-00002","article-title":"Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy","volume":"69","author":"Smith","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2014.01.875_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0891-5520(02)00038-7","article-title":"Blastomycosis","volume":"17","author":"Bradsher","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jaad.2014.01.875_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2036.2009.04112.x","article-title":"Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease","volume":"31","author":"Shale","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2014.01.875_bib11","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jaad.2012.04.036","article-title":"Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management","volume":"67","author":"Abramson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.01.875_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jaad.2014.01.875_bib13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2007.081513","article-title":"The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease","volume":"67","author":"Cepeda","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2014.01.875_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrrheum.2009.279","article-title":"Tumor necrosis factor bloackade and the risk of viral infection","volume":"6","author":"Kim","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaad.2014.01.875_bib15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3 year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2014.01.875_bib16","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2014.01.875_bib17","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/rheumatology\/kes030","article-title":"Mucocutaneous leishmaniasis in a patient treated with anti-TNF-\u03b1 therapy","volume":"51","author":"Garcia-Gonzalez","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2014.01.875_bib18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1469-0691.2011.03674.x","article-title":"Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe","volume":"18","author":"Zanger","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaad.2014.01.875_bib19","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/art.20882","article-title":"Clinical infection with Strongyloides sterocoralis following etanercept use for rheumatoid arthritis","volume":"52","author":"Boatright","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2014.01.875_bib20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/RHU.0b013e3180690933","article-title":"Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy","volume":"13","author":"Krishnamurthy","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaad.2014.01.875_bib21","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1086\/322707","article-title":"Diagnosis of Strongyloides stercoralis infection","volume":"33","author":"Siddiqui","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2014.01.875_bib22","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1086\/508538","article-title":"Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists","volume":"43","author":"Tubach","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2014.01.875_bib23","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/377235","article-title":"Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists","volume":"37","author":"Gottlieb","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2014.01.875_bib24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1128\/CMR.00007-11","article-title":"Sporothrix schenckii and Sporotrichosis","volume":"24","author":"Barros","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2014.01.875_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2014.01.875_bib26","first-page":"854","article-title":"Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience","volume":"26","author":"Pena-Sagredo","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2014.01.875_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1128\/CMR.4.2.169","article-title":"Epidemiology of human listeriosis","volume":"4","author":"Schuchat","year":"1991","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2014.01.875_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid1901.120393","article-title":"Listeriosis outbreaks and associated food vehicles, United States, 1998-2008","volume":"19","author":"Cartwright","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jaad.2014.01.875_bib29","first-page":"1357","article-title":"Multistate outbreak of listeriosis associated with Jensen Farms cantaloupe\u2014United States, August-September 2011","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2014.01.875_bib30","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/art.33481","article-title":"Clinical\u00a0image: salmonella mycotic aneurysm in a patient receiving etanercept for rheumatoid arthritis","volume":"64","author":"Qutre","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2014.01.875_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jinf.2008.03.012","article-title":"Salmonella infections in immunocompromised adults","volume":"56","author":"Gordon","year":"2008","journal-title":"J Infect"},{"key":"10.1016\/j.jaad.2014.01.875_bib32","first-page":"41","article-title":"Surveillance for foodborne disease outbreaks\u2014United States, 2009-2010","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2014.01.875_bib33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.clindermatol.2012.01.005","article-title":"Cryptococcosis","volume":"30","author":"Negroni","year":"2012","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2014.01.875_bib34","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jaad.2008.12.041","article-title":"Aggressive cutaneous infection with Mycobacterium marinum in two patients receiving anti-tumor necrosis factor-alfa agents","volume":"65","author":"Caron","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.01.875_bib35","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2012.118","article-title":"Mycobacterium marinum: an increasingly common opportunistic infection in patients on infliximab","volume":"107","author":"Ferreira","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2014.01.875_bib36","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.crohns.2012.04.015","article-title":"A case of opportunistic skin infection with Mycobacterium marinum during adalimumab treatment in a patient with Crohn\u2019s disease","volume":"7","author":"Kump","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaad.2014.01.875_bib37","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1056\/NEJMc051556","article-title":"Infliximab and reactivation of cerebral toxoplasmosis","volume":"353","author":"Young","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.01.875_bib38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.semarthrit.2006.08.004","article-title":"Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis","volume":"36","author":"Lassoued","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2014.01.875_bib39","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2014.01.875_bib40","first-page":"1433","article-title":"Multistate outbreak of human Salmonella typhimurium infections associated with aquatic frogs\u2014United States, 2009","volume":"58","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2014.01.875_bib41","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1086\/381594","article-title":"Reptiles, amphibians, and human Salmonella infection: a\u00a0population-based, case-control study","volume":"38","author":"Mermin","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2014.01.875_bib42","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1093\/cid\/cir703","article-title":"Updates on human papillomavirus and genital warts and counseling messages from the 2010 Sexually Transmitted Diseases Treatment Guidelines","volume":"53","author":"Dunne","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2014.01.875_bib43","first-page":"C4480","article-title":"Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment","volume":"59","author":"Nordgaard-Lassen","year":"2012","journal-title":"Dan Med J"},{"key":"10.1016\/j.jaad.2014.01.875_bib44","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1086\/605498","article-title":"Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors","volume":"49","author":"Bradford","year":"2009","journal-title":"Clin Infect Dis"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214010068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214010068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:30:21Z","timestamp":1759271421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214010068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0190962214010068"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.01.875","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor\u2013alfa antagonists","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.01.875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}